Cat. No.: DAB-0012018
Product Information | |
---|---|
Clonality | Monoclonal |
Isotype | IgG |
Host Species | Rabbit |
Reactivity | Human, Mouse, Rat |
Applications | WB |
Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val106 of human FBP1/FBPase 1 protein. |
Format | Liquid |
Purity | Affinity purity |
Target Information | |
---|---|
Target Name | FBP1 |
UniProt No. | P09467 |
Gene ID | 2203 |
Gene Description | Fructose-1, 6-bisphosphatase 1, a rate limiting enzyme in gluconeogenesis, catalyzes the conversion of fructose-1, 6-bisphosphate to fructose-6-phosphate. Inhibition of FBP1 expression in basal-like breast cancer cells leads to metabolic reprogramming, including enhanced glycolysis, which leads to increased glucose uptake, biosynthesis of macromolecules, and activation of PKM2. This metabolic reprogramming endows tumor cells with cancer stem cell -like properties, thereby increasing their tumorigenicity. Depletion of FBP1 was also reported in more than 600 clear cell renal cell carcinoma tumors, suggesting that FBP1 may inhibit ccRCC tumor progression. |
Shipping & Storage | |
---|---|
Shipping | Shipped at 4 °C. |
Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.